Tounjian Advisory Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Tounjian Advisory Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.3K	Buy	+49	New	+$21.7K	0.01%	286

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Tounjian Advisory Partners's VRTX Position: Q2 2026 in Review

Tounjian Advisory Partners opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 49 shares worth $24.3K. The stake represents 0.01% of the portfolio and ranks #286 among its holdings.

1,091 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Tounjian Advisory Partners held 49 shares of Vertex Pharmaceuticals worth $24.3K as of Q2 2026.
Vertex Pharmaceuticals was a new Tounjian Advisory Partners position in Q2 2026.
Vertex Pharmaceuticals made up 0.01% of Tounjian Advisory Partners's portfolio in Q2 2026, its #286 holding.
1,091 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Tounjian Advisory Partners's 13F filing for Q2 2026, filed 7 Aug 2026.